| Description | Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody that is a potent ICOS agonist. Vopratelimab has a high affinity for inducible T cell CO stimulating factors (ICOS), with an affinity of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. Vopratelimab has an anti-tumor immune effect and can be used to improve metastatic non-small cell lung cancer. |
| In vitro | Vopratelimab（JTX-2011；0.001-10 μg/mL；3天；CD4 T细胞）展现了激活初级人类T细胞的活性，促进分泌IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα和IL-21[1]。 |
| In vivo | Vopratelimab（JTX-2011；0.25-0.3 mg/kg；i.p.；每周两次，连续两周）在Sa1/N 同源小鼠肿瘤模型中促进肿瘤退化[1]。 |
| Synonyms | JTX 2011 |
| molecular weight | N/A |
| CAS | 2039148-04-2 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595. |